CAMBRIDGE, Mass.– Bifrost Biosystems, a pioneer in Optical Pooled Screening (OPS) technologies, today announced the appointment of experienced life sciences industry executive, Jonas Jarvius, PhD, as Chief Executive Officer, President and Director. He brings to Bifrost over 15 years of C-level executive experience from both private and public companies translating innovative technologies into commercial products that impact human health outcomes.
“On behalf of our board of directors, we enthusiastically welcome Jonas to his new role as President and CEO of Bifrost and look forward to the many successes ahead for him and the team,” said Shawn Marcell, co-founder and Chairman of Bifrost. “Jonas’s strong technical background combined with his demonstrated business acumen will bring a level of rigor and visionary leadership essential to driving Bifrost’s success.”
Dr. Jarvius earned his doctoral degree in Molecular Medicine from Uppsala University where his research focused on developing Proximity Ligation and Padlock probe-based molecular recognition technologies as well as isothermal amplification techniques. Several of these technologies have subsequently been commercialized in successful companies such as Olink, Q-linea, Umbrella Science, and Sigolis (Ginolis) where Jonas is a founder or cofounder. Dr. Jarvius most recently served as chief executive officer of Q-Linea, a diagnostics company focused on improving sepsis treatment and reducing antimicrobial resistance. In this role, he led the company from an initial technology to a multinational commercial enterprise.
“I am excited to lead Bifrost and work with such an exceptionally talented team,” said Jonas. “In my career, I have had the good fortune of developing and commercializing disruptive technologies in protein interaction analysis, rapid Antibiotic Susceptibility Testing and advanced microfluidics. The Bifrost OPS technology is similarly well-positioned to disrupt drug discovery and empower researchers to make better-informed decisions.”
Bifrost’s advanced OPS platform revolutionizes functional genomics through high-speed, microscopy-based pooled single-cell screens of CRISPR-based perturbations. The resulting extensive dataset facilitates understanding of complex biological processes, target identification and validation – actionable insights that accelerate discovery pipelines in biological research.
